Product DNN.31.19.026 not checked
Ache Laboratorios Farmaceuticos S.A.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ocular Hypertension, Primary Open Angle Glaucoma
- Main trialPhase 3
- “This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.”In the company’s words, NCT07617532 on ClinicalTrials.gov
- Given with
- Cosopt (Thea Pharma)Other companies’ drugs in its trials
Other drugs for Ocular Hypertension
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- HUC3-637Huons Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Bimatoprost Implant SystemSpyGlass Pharma, Inc. · Phase 3
- Citicoline eye drops 2%Omikron Italia S.r.l. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
Coming up1
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Mar 2028 | Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026